AAPGV Ascentage Pharma Group International Kapitallashuvning sof aktivlarga nisbati

Ascentage (AAPGV) kompaniyasining rasmiy ramzlari

Ascentage Pharma Group (AAPGV) apoptoz inhibitorlarini global leykoz terapiya protokollariga integratsiya qilish orqali o'simta dori vositalariga chidamlilikka qarshi kurashish usullarini ishlab chiqmoqda. Ushbu biofarmatsevtika tarmig'i olverembatinib dorisi va klinikalarni kompaniyaning molekulalari bilan bog'lovchi strategik ittifoqlarga asoslangan. Biznes mustaqil rivojlanish sikliga tayanadi, bu esa uni himoya aktiviga aylantiradi. GURU.Markets platformasida kitob qiymatiga nisbatan narx ko'rsatkichi investitsiya xavfsizligini namoyish etadi, bunda joriy qiymat 16.67 ni tashkil etadi.

AAPGV: Ascentage Kapitallashuvning sof aktivlarga nisbati 25.01.2025 - 28.10.2026

AAPGV (Ascentage Pharma Group International): tahliliy kesimlar va indikatorlar boʻyicha maʼlumotlar

- narx va narxlar bo'yicha konsensus prognoz:
Aksiya narxi Ascentage Pharma Group|AAPGV - Tahlilchilar maqsadlari diapazoni
- bozor kapitallashuvi bo'yicha ma'lumotlar:
Bozor bahosi Ascentage Pharma Group Ltd|AAPGV - Kompaniyaning to‘liq qiymati
- balans kapitallashuvi bo'yicha ma'lumotlar:
Bitta aksiya hisobiga balans qiymati Ascentage Pharma|AAPGV - Kompaniyaning sof aktivlari|Bozor kapitallashuvining balans qiymatiga nisbati ascentage.com|AAPGV - Kompaniyaning umumiy aktivlari
- qarz va likvidlik bo'yicha ma'lumotlar:
Qarzning xususiy kapitalga nisbati Ascentage Pharma Group|AAPGV - Uzoq muddatli qarzning kapitalga nisbati ko'rsatkichi|Qisqa muddatli qarzning kapitalga nisbati Ascentage Pharma Group Ltd|AAPGV - Kompaniyaning umumiy qarzi|Balans kapitallashuviga qarzlar Ascentage Pharma Group Ltd
Kompaniyaning dastlabki tahlili:Ascentage Pharma Group
Ascentage Pharma Group International asosiy tovari

Klinik sinovlar natijalariga bog'liq bo'lgan Ascentage Pharma Group (AAPGV) xususiyatlari bozor qiymatining buxgalteriya qiymatiga nisbati tendentsiyasining tebranishlarini keltirib chiqaradi. Ushbu ko'rsatkich kompaniyaning joriy birja bahosini uning sof aktivlarining buxgalteriya qiymati bilan solishtiradi. Ushbu raqamlar orasidagi farq kelajakdagi dori vositalari nomzodlariga bo'lgan bozor kutuvlarini aks ettiradi. Operatsion daromadga ega bo'lmagan startap uchun ushbu metrika haqiqiy rezervlarga nisbatan kapitalning haddan tashqari yuqori baholanish darajasini o'lchaydi. Ushbu nisbatni tahlil qilish rivojlanish salohiyati uchun haddan tashqari ko'p to'lash xavfini baholash imkonini beradi.

Toʻgʻridan-toʻgʻri raqobatchilar

Bozor kapitallashuvining balans qiymatiga nisbati ONC (BeiGene Ltd)|Bozor qiymatining xususiy kapitalga nisbati halozyme.com|Kapitallashuvning sof aktivlarga nisbati Revolution Medicines, Inc.|Bozor qiymatining balans qiymatiga nisbati Ascentage Pharma Group International|Bozor kapitallashuvining balans qiymatiga nisbati CGON (CG Oncology Corp)|Kapitallashuvning sof aktivlarga nisbati UroGen Pharma Corp (URGN)|Bozor kapitallashuvining balans qiymatiga nisbati BCAX (Bicara Therapeutics Inc.)|personalis.com - Bozor kapitallashuvining balans qiymatiga nisbati|Erasca (ERAS) - Bozor qiymatining balans qiymatiga nisbati|DCTH - Kapitallashuvning balans qiymatiga nisbati|YMAB (YmAbs) - Bozor kapitallashuvining balans qiymatiga nisbati|Aura Corp (AURA) - Kapitallashuvning sof aktivlarga nisbati|Bozor kapitallashuvining balans qiymatiga nisbati CADL (Candel Therapeutics Inc.)|Bozor qiymatining balans qiymatiga koeffitsiyenti ARAY|SELLAS Life Sciences (SLS) - Bozor qiymatining balans qiymatiga nisbati|Balans qiymatiga nisbatan bozor qiymati Actuate Therapeutics Inc. ACTU|Kapitallashuvning sof aktivlarga nisbati Citius Oncology, Inc|Balans qiymatiga nisbatan bozor qiymati TuHURA Biosciences Inc. HURA|TARA: Bozor kapitallashuvining balans qiymatiga nisbati|fatetherapeutics.com (FATE) - Kapitallashuvning sof aktivlarga nisbati|WHWK: Kapitallashuvning sof aktivlarga nisbati|TCRX (TScan Therapeutics, Inc.) - Bozor kapitallashuvining balans qiymatiga nisbati|CSBR - Bozor qiymatining balans qiymatiga nisbati|Balans qiymatiga nisbatan bozor qiymati XBiotech USA|CEL-SCI Corporation - Bozor kapitallashuvining balans qiymatiga nisbati|Bozor qiymatining balans qiymatiga koeffitsiyenti ostherapies.com (OSTX)|Bozor kapitallashuvining balans qiymatiga nisbati RADX (Radiopharm Theranostics)|Artiva Biotherapeutics Inc. - Bozor kapitallashuvining balans qiymatiga nisbati|Bozor qiymatining balans qiymatiga nisbati ANL (Adlai Nortye Limited)|VERU - Balans qiymatiga nisbatan bozor kapitallashuvi|TPST (Tempest Therapeutics) - Bozor kapitallashuvining balans qiymatiga nisbati|Xilio Therapeutics (XLO) - Kapitallashuvning sof aktivlarga nisbati|Bozor kapitallashuvining balans qiymatiga nisbati RENB (Renovaro Biosciences)|Bozor qiymatining balans qiymatiga koeffitsiyenti MURA|Bozor qiymatining balans qiymatiga nisbati Kairos Pharma Ltd KAPA|Kapitallashuvning balans qiymatiga nisbati onkuretherapeutics.com OKUR|Kapitallashuvning sof aktivlarga nisbati CytoMed Therapeutics Limited (GDTC)|Bozor kapitallashuvining balans qiymatiga multiplikatori Curis Inc. CRIS|Apollomics Corp - Bozor kapitallashuvining balans qiymatiga nisbati|THAR - Bozor kapitallashuvining balans qiymatiga nisbati|Bozor kapitallashuvining balans qiymatiga nisbati ADVB (advanbiomed.com)|Genprex Inc (GNPX) - Bozor qiymatining xususiy kapitalga nisbati|Bozor kapitallashuvining balans qiymatiga nisbati CLDI (Calidi Biotherapeutics Inc.)|Bozor qiymatining balans qiymatiga koeffitsiyenti sunshinebiopharma.com (SBFM)|Xenetic Biosciences (XBIO) - Kapitallashuvning sof aktivlarga nisbati|Balans qiymatiga nisbatan bozor qiymati SLRX (Salarius Pharmaceuticals Inc)|Purple Biotech Corp (PPBT) - Bozor qiymatining balans qiymatiga nisbati|Sof aktivlarga nisbatan bozor kapitallashuvi American Oncology Network Inc AONC|Bozor kapitallashuvining balans qiymatiga nisbati BeiGene, Ltd. (BGNE)|CKPT - Balans qiymatiga nisbatan bozor qiymati|ELEV: Bozor kapitallashuvining balans qiymatiga nisbati|ICAD (iCAD) - Bozor kapitallashuvining balans qiymatiga nisbati|IKNA - Bozor qiymatining balans qiymatiga nisbati|Balans qiymatiga nisbatan bozor qiymati NTBL|Bozor qiymatining balans qiymatiga nisbati VIRX (Viracta Therapeutics)|Kapitallashuvning sof aktivlarga nisbati morphosys.com (MOR)|Bozor kapitallashuvining balans qiymatiga nisbati NAYA (NAYA Biosciences Inc.)